The best non-injection weight loss medication available in the UK right now

Wegovy tablets: what the trial data showed

The OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, and ran for 64 weeks. Participants taking oral semaglutide alongside lifestyle changes lost an average of around 13.6% of body weight compared with around 2.4% on placebo. Among those who stayed fully adherent throughout, average weight loss reached approximately 16–17%. Both figures come from the Novo Nordisk UK announcement accompanying the MHRA's approval in June 2026, and the difference between them is worth understanding: the 13.6% is the intention-to-treat average across everyone who started (including those who reduced their dose or stopped early) which makes it the more realistic benchmark for most people.

The most common side effects in OASIS 4 were gastrointestinal: nausea, diarrhoea, constipation and vomiting, reported in around 74% of the oral semaglutide group compared with 42% of the placebo group. Most were mild to moderate and tended to settle as the body adjusted. The titration schedule starts at 1.5mg daily and steps up through 4mg and 9mg to a 25mg maintenance dose, with at least one month at each level. More on how non-injection weight loss medication works in practice is worth reading if you are deciding between oral and injectable routes.

The tablet is taken first thing in the morning on an empty stomach, with a small amount of plain water, and you wait at least 30 minutes before any food, drink or other medicines. No refrigeration is needed, which many people find genuinely convenient for travel and daily routine.

Orlistat: the longer-established oral option

Orlistat has been licensed in the UK for many years and works entirely differently from GLP-1 medicines. It inhibits pancreatic lipase, blocking absorption of roughly a third of the fat consumed in a meal. It does not act on appetite signalling or gut hormones. Average weight loss in trials was more modest than GLP-1 data (around 3–5% more than placebo over one year in most analyses) and effectiveness depends heavily on maintaining a low-fat diet, because consuming high-fat meals while taking it causes unpleasant gastrointestinal effects. The NHS orlistat medicines page covers these points clearly.

A 60mg version is available over the counter (as Alli); the 120mg prescription-strength version requires a prescriber. Neither is dispensed by nume, but the distinction matters for anyone comparing options. For people who cannot tolerate GLP-1 side effects or who have contraindications, orlistat remains a licensed tool, though the weight-loss results are substantially smaller than those seen with semaglutide or tirzepatide.

There is a misconception worth letting go of here: that oral medicines are automatically gentler or less serious than injections. The GI side-effect rate with Wegovy tablets in OASIS 4 was higher than with the injection form in STEP 1. Oral does not mean milder, it means a different route of administration, with its own profile.

How Wegovy tablets sit alongside the injection options

It is useful to understand where the tablet fits relative to injectable weight loss medication. The Wegovy 2.4mg weekly injection produced around 15% average weight loss over 68 weeks in the STEP 1 trial. The 7.2mg pen, approved by the MHRA in April 2026, showed approximately 20.7% over 72 weeks in trials. Tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, reached around 20–21% at its highest dose in SURMOUNT-1. The NICE appraisal of tirzepatide (TA1026) documents these comparisons for anyone who wants to read the regulator's assessment directly.

Wegovy tablets sit below all three on average weight-loss magnitude in the published data so far. That is not a reason to dismiss them, for someone who genuinely cannot manage a weekly injection, a 13–17% loss with a once-daily tablet is clinically meaningful. It is a reason to have the conversation with a prescriber who can weigh your full picture. Our weight loss treatments page shows the options currently dispensed through nume.

If you are curious about the practical realities of the injection side, including whether the needle puts you off or you are simply gathering information, our page on weight loss injectable medication covers how these treatments work alongside a straightforward read that demystifies the process. And how weight loss injection medication is used is useful if you want to go further into the practicalities.

Eligibility and what a prescriber considers

Wegovy tablets are licensed for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Orlistat has broadly similar eligibility criteria.

Suitability for any of these medicines is not a box-ticking exercise. A prescriber looks at other medicines you take, your medical history, whether you have a history of pancreatitis or certain other conditions, and what your goals are. Wegovy tablets are not recommended in pregnancy, breastfeeding, or if you are trying to conceive, and they are not licensed for under-18s. Oral contraceptive absorption may be affected during treatment, your prescriber will cover this.

The potential downsides of weight loss injections page is useful context if you are specifically weighing the non-injection route against injectable alternatives. And for a broader view of what is available, a rundown of the named injectable medicines provides the comparison across the injection options. For questions our prescribers hear regularly, the FAQs cover the most common ones. Start your free consultation at any point to have your specific situation reviewed.